Intra-Arterial Chemotherapy is Reliable in Preventing High-Risk Superficial Bladder Cancer from Recurrence and Progression

REFERENCES

• Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortalityand recurrence. J Urol 2000; 164(3 Pt 1): 680-684.
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta-Ti bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49 (3): 466-5; discussion 475-7.
   Google Scholar
• Huncharek M, Geschwind J-F, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary su-perficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 2000; 53 (7): 676–680.
   PubMed Web of Science ®Google Scholar
• Huncharek M, McGarry R, Kupelnick B. Impact of intrav-esical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analy-sis. Anticancer Res 2001; 21 (1B): 765-770.
   Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in Patients with superficial bladder cancer: a meta-analysis of the pub-lished results of randomized clinical trials. J Urol 2002; 168 (5): 1964–1970.
   PubMed Web of Science ®Google Scholar
• Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystec-tomy for clinical stage Ti transitional cell carcinoma of the blad-der. Semin Urol Oncol. 1997;15 (3): 154–60.
   PubMedGoogle Scholar
• Masood S, Sriprasad S, Palmer JH, Mufti GR. T1G3 blad-der cancer-indications for early cystectomy. Int Urol Nephrol. 2004; 36 (1): 41–4.
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol. 2004 Jul; 172 (1): 70–5.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Ti bladder can-cer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171(6 Pt 1): 2186-90.
   Google Scholar
• Böhle A, Jocham D, Bock PR. Intravesical Bacillus Cal-mette-Guerin Versus Mitomycin C For Superficial Bladder Can-cer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity. J Urol. 2003; 169 (1): 90–5.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Furukawa A, Takahashi M, Murata K. Neoadjuvant Intra-Arterial Chemotherapy for Locally Advanced Uterine Cervical Cancer: Clinical Efficacy and Factors Influencing Response. Cardiovasc Intervent Radiol. 2003; 26 (3): 234–41.
   PubMed Web of Science ®Google Scholar
• Miyanaga N, Akaza H, Okumura T, Sekido N, Kawai K, Shimazui T, et al. A bladder preservation regimen using intra-ar-terial chemotherapy and radiotherapy for invasive bladder can-cer: a prospective study. Int J Urol. 2000; 7 (2): 41–8.
   PubMed Web of Science ®Google Scholar
• Mori K, Nomata K, Noguchi M, Eguchi J, Hayashi N, Kanetake H. Long-term follow up of patients with invasive blad-der carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy. Int J Urol. 2007; 14 (7): 591–4.
   PubMed Web of Science ®Google Scholar
• Zhou FJ, Yu SL, Li YH, Liu ZW, Xiong YH, Wu PH, et al. Intra-arterial chemotherapy with gemcitabine and cisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis. J Chemother 2009; 21 (1): 91–97.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18 (17): 3068–77.
   PubMed Web of Science ®Google Scholar
• Geller NL, Pocock SJ. Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners. Bio-metrics 1987; 43: 213–23.
   PubMed Web of Science ®Google Scholar
• Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials. 1984; 5: 348–61.
   PubMedGoogle Scholar
• Oosterlinck W, van der Meijden A, Sylvester R, Böhle A, Rintala E, Solsona Narvón E, et al. European Association of Urol-ogy Guideline on TaT1 (Non-muscle invasive) bladder cancer. edition 2007: 0-24, Arnhem, Netherlands.
   Google Scholar
• Cookson M, Herr HW, Zhang ZF, Soloway S, Sogani P, Fair W. The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome. J Urol. 1997; 158 (1): 62–7.
   PubMed Web of Science ®Google Scholar
• Saika T, Tsushima T, Nasu Y, Arata R, Kaku H, Kusaka N, et al. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy. Jpn J Clin Oncol. 2002; 32 (11): 461–5.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Kakizaki H, Numasawa K, Suzuki K, Kato H. Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer. Eur Urol. 1989; 16 (3): 189–94.
   PubMed Web of Science ®Google Scholar
• Kuroiwa T, Naito S, Hasuo K, Kishikawa T, Masuda K, Kumazawa J. Phase II study of a new combined primary chemotherapy regimen, intravenous methotrexate and vincristine and intraarterial adriamycin and cisplatin, for locally advanced urinary bladder cancer: preliminary results. Cancer Chemother Pharmacol. 1995; 35 (5): 357–63.
   PubMed Web of Science ®Google Scholar
• Tsukamoto S, Ishikawa S, Tsutsumi M, Nakajima K, Sug-ahara S. An organ-sparing treatment using combined intra-arte-rial chemotherapy and radiotherapy for muscle-invading bladder carcinoma. Scand J Urol Nephrol. 2002; 36 (5): 339–43.
   PubMed Web of Science ®Google Scholar
• Engeler DS, Wyler S, Neyer M, Hobi C, Muller J, Schmid HP. Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: A prospective evaluation in a consecutive series of 210 cases. Scand J Urol Nephrol. 2008; 42 (6): 522–7.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Witjes WP, Idema JG, Kums JJ, van Vierssen Trip OB, de Bruin MJ,et al. Comparison of three sched-ules of intravesical epirubicin in patients with non-muscle-inva-sive bladder cancer. Eur Urol. 2008; 53 (5): 984-91. Epub 2007 Dec 27.
   Google Scholar
• Hideyuki Akaza, Seiji Naito, Michiyuki Usami, Tsuneharu Miki, Naoto Miyanaga, Hisashi Taniai, et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell car-cinoma after cisplatin-containing therapy: a Japanese experi-ence. Jpn J Clin Oncol. 2007; 37 (3): 201–6.
   PubMed Web of Science ®Google Scholar